Novartis (NVS) announced that it had achieved positive results in two phase 2 studies using IND/GLY/MF to treat patients with asthma. IND/GLY/MF, also known as QVM149, was superior to the standard of care in both of these studies. In addition, on the safety front, the company's drug had a comparable safety profile to placebo and Advair. QVM149 is currently in phase 3 studies, but Novartis will make additional results from the mid-stage study available in the coming months at medical conferences. It hopes to highlight the path forward for a potential regulatory filing